Principal Investigator
Craig Moskowitz
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20231098
Clinical Trial Summary
PRIMAVERA: A Modular Phase I/II, Open-label, Multicentre
Study to Evaluate the Safety, Tolerability, and Efficacy of
AZD3470, a PRMT5 Inhibitor, as Monotherapy and in
Combination With Anticancer Agent(s) in Participants With
Relapsed/Refractory Haematologic Malignancies
Phase
Phase I/II
Funding Agency/Sponsor
Industrial
Disease
Lymphoma
Contact Information
Phone Number
305-243-2647